Pomerantz Law Firm Warns Investors About Regeneron Class Action Lawsuit and Critical Deadlines
In a significant alert for investors, Pomerantz LLP has announced the filing of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) aimed at addressing issues related to potential securities fraud and unlawful business practices. Those who have incurred losses due to their investment in Regeneron are encouraged to reach out to Danielle Peyton at the firm before the critical deadline of September 14, 2026, to discuss their options and possibly join the lawsuit as lead plaintiffs.
The class action is rooted in revelations made during Regeneron's first quarter earnings call on April 29, 2026. During this call, the company disclosed an alteration in the Phase III Fianlimab-Libtayo Study, specifically expanding the pool of patients eligible for the analysis of progression-free survival. This announcement triggered a substantial drop in Regeneron's stock price, which fell by $45.41 per share, amounting to a decline of 6.21%, closing at $686.36.
Further compounding the situation, on May 15, 2026, Regeneron released additional information regarding the Phase 3 Trial of Fianlimab, stating that it did not achieve statistical significance for its primary endpoint regarding improvement in progression-free survival (PFS). This news resulted in a further decline in share value of $68.57 or 9.82%, bringing the closing price down to $629.68 per share on May 16, 2026. These announcements raised serious questions about the transparency of Regeneron's business practices and the decisions made by its management.
The Pomerantz Law Firm has a long-standing reputation for its dedication to protecting the rights of investors affected by potential corporate misconduct. They have been at the forefront of securities class actions and have a proven track record of recovering millions in damages for their clients. Founded over 85 years ago by Abraham L. Pomerantz, the firm continues to uphold his legacy by pursuing justice for victims of securities fraud.
Investors who think they might be eligible for this class action are urged to act quickly. The deadline for expressing interest in becoming a lead plaintiff is September 14, 2026. Those interested should contact the Pomerantz firm via email at [email protected], or by phone at 646-581-9980. Including information such as mailing address, telephone number, and the number of shares purchased is recommended to expedite the process.
For more information, investors can access a copy of the complaint filed against Regeneron through the Pomerantz website. As the situation develops, stakeholders in the pharmaceutical sector and financial analysts alike will be closely monitoring the impact of this lawsuit on Regeneron's market position and overall reputation. This upcoming class action lawsuit signifies a crucial chapter for those who've suffered financial losses linked to Regeneron and emphasizes the necessity for accountability in corporate governance. Investors are advised to remain vigilant and informed about this evolving scenario.
The class action is rooted in revelations made during Regeneron's first quarter earnings call on April 29, 2026. During this call, the company disclosed an alteration in the Phase III Fianlimab-Libtayo Study, specifically expanding the pool of patients eligible for the analysis of progression-free survival. This announcement triggered a substantial drop in Regeneron's stock price, which fell by $45.41 per share, amounting to a decline of 6.21%, closing at $686.36.
Further compounding the situation, on May 15, 2026, Regeneron released additional information regarding the Phase 3 Trial of Fianlimab, stating that it did not achieve statistical significance for its primary endpoint regarding improvement in progression-free survival (PFS). This news resulted in a further decline in share value of $68.57 or 9.82%, bringing the closing price down to $629.68 per share on May 16, 2026. These announcements raised serious questions about the transparency of Regeneron's business practices and the decisions made by its management.
The Pomerantz Law Firm has a long-standing reputation for its dedication to protecting the rights of investors affected by potential corporate misconduct. They have been at the forefront of securities class actions and have a proven track record of recovering millions in damages for their clients. Founded over 85 years ago by Abraham L. Pomerantz, the firm continues to uphold his legacy by pursuing justice for victims of securities fraud.
Investors who think they might be eligible for this class action are urged to act quickly. The deadline for expressing interest in becoming a lead plaintiff is September 14, 2026. Those interested should contact the Pomerantz firm via email at [email protected], or by phone at 646-581-9980. Including information such as mailing address, telephone number, and the number of shares purchased is recommended to expedite the process.
For more information, investors can access a copy of the complaint filed against Regeneron through the Pomerantz website. As the situation develops, stakeholders in the pharmaceutical sector and financial analysts alike will be closely monitoring the impact of this lawsuit on Regeneron's market position and overall reputation. This upcoming class action lawsuit signifies a crucial chapter for those who've suffered financial losses linked to Regeneron and emphasizes the necessity for accountability in corporate governance. Investors are advised to remain vigilant and informed about this evolving scenario.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.